GlobeNewswire Inc.··Zymeworks Inc.Zymeworks Advances Oncology Pipeline With RAS-Targeting ADCs at AACR 2026
Zymeworks presents six ADC program updates at AACR 2026, including Phase 1 ZW191 clinical data and novel RAS-targeting platform preclinical results.
ZYMEantibody-drug conjugateoncology